Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Drugs. 2018 Mar;78(3):389-396. doi: 10.1007/s40265-018-0877-7.
Netarsudil ophthalmic solution 0.02% (hereafter referred to as netarsudil 0.02%) [Rhopressa] is a Rho-associated protein kinase inhibitor that is thought to lower intraocular pressure (IOP) by increasing aqueous humour outflow through the trabecular meshwork. It has been developed by Aerie Pharmaceuticals and was recently approved in the USA for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension. The recommended dosage is one drop in the affected eye(s) once daily in the evening. Phase III development in the EU and phase II development in Japan are underway for this indication. This article summarizes the milestones in the development of netarsudil 0.02% leading to this first approval for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension.
盐酸奈甲唑啉滴眼液 0.02%（以下简称奈甲唑啉 0.02%）[Rhopressa]是一种 Rho 相关蛋白激酶抑制剂，据认为通过增加房水通过小梁网流出来降低眼内压（IOP）。它由 Aerie 制药公司开发，最近在美国获得批准，用于降低开角型青光眼或高眼压症患者的升高的 IOP。推荐剂量为每晚一次，每次一滴滴入受影响的眼睛。该适应症在欧盟的 III 期开发和日本的 II 期开发正在进行中。本文总结了奈甲唑啉 0.02% 的开发里程碑，最终首次批准该药物用于降低开角型青光眼或高眼压症患者的升高的 IOP。
